Navigation Links
REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide
Date:11/6/2007

severely active Crohn's

disease who have had an inadequate response to conventional therapy.

About REMICADE

REMICADE is a monoclonal antibody that specifically targets TNF-alpha, which has been shown to play a role in Crohn's disease (CD), rheumatoid arthritis (RA), ankylosing spondylitis (AS) psoriatic arthritis (PsA), ulcerative colitis (UC), pediatric Crohn's disease (PCD) and psoriasis (PsO). REMICADE is the global market leader among anti-tumor necrosis factor alpha (TNF-alpha) therapies and the only agent approved globally in the 3 regions of North America, the EU and Japan for the treatment of both RA and CD. Additionally, REMICADE is the only anti-TNF approved in three different therapeutic areas: gastroenterology, rheumatology and dermatology. The safety and efficacy of REMICADE have been well established in clinical trials over the past 15 years and through commercial experience with more than one million patients treated worldwide.

In the U.S., REMICADE, in combination with methotrexate, is indicated for reducing signs and symptoms, inhibiting the progression of structural damage and improving physical function in patients with moderately to severely active RA. REMICADE is the only biologic indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult and pediatric patients with moderately to severely active CD who have had an inadequate response to conventional therapy. REMICADE is also indicated for reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in patients with fistulizing CD. In December 2004, REMICADE was approved for reducing signs and symptoms in patients with active AS. In May 2005, REMICADE was approved for reducing signs and symptoms of active arthritis in patients with PsA. Additionally, in September 2005, REMICADE was approved for reducing signs and symptoms, achieving clinical remission and mucosal healing, and eliminati
'/>"/>

SOURCE Centocor, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. BioStorage Technologies Becomes Green Powered through the Use of 100% Certified Renewable Energy
2. Haemonetics Becomes Preferred Provider of Plasma Collection Products to Octapharma Europe
3. Prof. Michel Klein Becomes Chief Scientific Officer at AMVAC
4. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
5. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
6. Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend
7. Genmab Announces 2007 First Half Year Results
8. Pharsight Achieves First License Sale for Public-Source Database
9. Novare Announces First Ever Single Port Laparoscopic Kidney Removal (Nephrectomy) Using RealHand(TM) HD Instruments
10. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
11. China Medical Technologies Reports First Quarter Financial Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...AI,Nov.24/PRNewswire-Asia/--ShanghaiBiolaxyannounc...)hasapprovedthe,investigationalnewdrugapplication(...insulinformulationtotreatdiabetes.ThisIND,approval.... , Diabetesisadisordercharacteristicofhighbl...betesoftenresultinseveremicro-and,macro-vasculardi...
(Date:11/24/2009)... The FBI recently approved the Promega ...ticipating in or generating DNA records for the Na... Madison, WI USA (PRWEB) -- The FBI recently appr... use by laboratories participating in, or generati...(NDIS). NDIS currently contains more than seven mi...
(Date:11/24/2009)...TURE:HTL , TORONTO,Nov.24/PRNewswire-FirstCal...pitalInc.,aleadingproviderofadvancedlasersystemsan...icmarkets,todayreportedoperationalandfinancialresu...2009Highlights,-Revenuewas$1.46millioncomparedwit...centcomparedwith66.1percentinQ3,2008,-Netlossreduc...
(Date:11/24/2009)...GO,Nov.24,2009/PRNewswire-FirstCall/--ArenaPharmac...ecompanyisscheduledtopresentatthePiperJaffray21stA...m.EasternTime(8:30a.m.PacificTime)attheNewYorkPala...dChiefExecutiveOfficer,isscheduledtoprovideanoverv...discoveryprograms. ,, Aliveaudiowebcastofthepre...
Breaking Biology Technology:Biolaxy Secures IND Approval for Oral Insulin 2NDIS Approval of Promega PowerPlex Kit Clears Path for More DNA Profiles to be Added to U.S. Database 2Hamilton Thorne announces third quarter results 2Hamilton Thorne announces third quarter results 3Hamilton Thorne announces third quarter results 4Hamilton Thorne announces third quarter results 5Hamilton Thorne announces third quarter results 6Hamilton Thorne announces third quarter results 7Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 2
...O, Oct. 14 Nile Therapeutics,Inc. (Nasdaq: NLTX ...ter,open-label Phase 2a clinical study of CD-NP, a...ospitalized for acute heart failure., -- Statis...ry wedge pressure -- Statistically signific...on in right atrial pressure -- Trend toward incr...
...pport creation of market incentives and facilitate...O Ventures for Global,Health (BVGH) today announce...anded its support of the organization, so it can f... create new medicines for infectious,diseases of t...p BVGH build,the market case for biotechnology ind...
...ct. 14 Althea Technologies, Inc., a leading,provi...armaceutical,development and manufacturing, announ...fast growth awards, Deloitte LLP,s San Diego Techn...00 Fastest Growing Private Companies,for the fifth... is an,annual ranking of the 50 fastest growing te...
Other Biology Technology:Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure 2Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure 3Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure 4Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure 5BIO Ventures for Global Health Receives $7 Million Grant from Gates Foundation to Engage Biotechnology in the Fight Against Neglected Diseases of the Developing World 2Althea Technologies Receives Fast Growth Honors: Deloitte Technology Fast 50 and San Diego Business Journal Fast 100 Awards for the Fifth Consecutive Year 2
(Date:11/23/2009)...e of day matters to forest trees dealing with drou...ch team led by Professor Malcolm Campbell, Univers...search and colleagues in the department of cell an...Capitalizing on their previous work to decode the ...ned how poplar trees use their 45,000 genes to res...
(Date:11/23/2009)...ipants gathered this week for the seventh annual N...ce. This year,s topic, "Synthetic Biology," brough...archers to explore the engineering, scientific, an...synthetic biology. , Bonnie L. Bassler, professo... this year,s conference chair, challenged the atte...
(Date:11/23/2009)...s "incontrovertible evidence" that the volcanic su...t 73,000 years ago deforested much of central Indi...s report. , The volcano ejected an estimated 800...ing a crater (now the world,s largest volcanic lak...ide. Ash from the event has been found in India, t...
Breaking Biology News(10 mins):Time of day matters to thirsty trees, U of T researcher discovers 2Synthetic biology offers new opportunities for interdisciplinary collaboration 2Supervolcano eruption -- in Sumatra -- deforested India 73,000 years ago 2Bausch 26 Lomb Vision Care Strengthens Its Commitment to ReNu 28R 29 Brand and the Eye Care Community 50159 1Bausch 26 Lomb Vision Care Strengthens Its Commitment to ReNu 28R 29 Brand and the Eye Care Community 50159 2Bausch 26 Lomb Vision Care Strengthens Its Commitment to ReNu 28R 29 Brand and the Eye Care Community 50159 3Positive CHMP Opinion for JAVLOR 28R 29 in Metastatic Treatment of Bladder Cancer After Failure of a Prior Platinum Containing Regimen 50155 1Positive CHMP Opinion for JAVLOR 28R 29 in Metastatic Treatment of Bladder Cancer After Failure of a Prior Platinum Containing Regimen 50155 2Positive CHMP Opinion for JAVLOR 28R 29 in Metastatic Treatment of Bladder Cancer After Failure of a Prior Platinum Containing Regimen 50155 3RainEarth Obtains Patent Approvals for Its Core Technology 50153 1RainEarth Obtains Patent Approvals for Its Core Technology 50153 2RainEarth Obtains Patent Approvals for Its Core Technology 50153 3
...ornia,s Viterbi School of Engineering have success...onic Transmission Tomography" (HUTT) system that o...o those produced by existing commercial X-ray, ult...essor of biomedical engineering at the Viterbi Sch...in San Diego at the 28th International Acoustical ...
...iversity of Melbourne, Australia, has conducted th...volution of one of nature,s most sophisticated bio...the March issue of the journal Genome Research. , ...amily Colubroidea, evolved glands for the storage ...million years ago. Since that time, various prey-i...
...tes stem from bat bites, far more people are treat...e list of most often reported rabid mammal. Contro...he spatial dynamics of the disease - where new out... In a new study reported in the freely-available o...ply a mathematical model to predict the likely spr...
Other Biology News:A probe, not an echo 2A probe, not an echo 3A probe, not an echo 4Venom doc tracks down snake bioweapons 2Rabies spread speeds up 2
Mouse Anti-Yersinia pestis Monoclonal Antibody, Unconjugated, Clone YPF19 from Abcam
Rabbit Anti-13,14 dihydro 15 keto Prostaglandin E2 Polyclonal Antibody, Unconjugated from Abcam
Mouse Anti-Human DDO Polyclonal Antibody, Unconjugated from ABR-Affinity BioReagents
Anti-Arginine Vasopressin Receptor Polyclonal Antibody, Unconjugated from CHEMICON
Biology Products: